Cel­gene stays fo­cused on pro­tein home­osta­sis, backs Cleave’s $37M round to fu­el ear­ly stud­ies

Cleave Bio­sciences CEO Lau­ra Shawver has built out her ven­ture syn­di­cate, adding can­cer pow­er­house Cel­gene to the mix and mak­ing key ad­di­tions to the board as her biotech team preps for the next stage of clin­i­cal de­vel­op­ment. The ex­pand­ed syn­di­cate is con­tribut­ing $37 mil­lion in fresh funds — bring­ing its to­tal to $91 mil­lion — to com­plete Cleave’s nav­i­ga­tion through a pair of ear­ly-stage can­cer drug stud­ies for its cru­cial lead pro­gram. And Cel­gene is demon­strat­ing its re­newed com­mit­ment to pro­tein home­osta­sis, a field that has in­spired a slate of deals in re­cent years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER